PolyPid

Yahoo Finance • 10 days ago

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive Phase 3 Trial Results Company Contin... Full story

Yahoo Finance • 16 days ago

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

PETACH TIKVA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company focused on improving surgical outcomes, today announced that D-PLEX₁₀₀, the company’s lead c... Full story

Yahoo Finance • 24 days ago

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

PETACH TIKVA, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2... Full story

Yahoo Finance • 2 months ago

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story

Yahoo Finance • 2 months ago

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

PETACH TIKVA, Israel, Sept. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dr. Shmuel Sharoni will present t... Full story

Yahoo Finance • 2 months ago

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

PETACH TIKVA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that management will be presenting at... Full story

Yahoo Finance • 3 months ago

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that senior management will participat... Full story

Yahoo Finance • 3 months ago

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

PETACH TIKVA, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dalit Hazan, Deputy CEO, EVP R&D,... Full story

Yahoo Finance • 3 months ago

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Positive Phase 3 SHIELD II Trial Results -D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI NDA submission expected in Q1 2026 Unveiled a Long-Acting GLP-1 Receptor Agonists Delivery Platform... Full story

Yahoo Finance • 3 months ago

PolyPid appoints Nurit Tweezer-Zaks as chief medical officer

* PolyPid  (NASDAQ:PYPD [https://seekingalpha.com/symbol/PYPD]) announced on Tuesday the appointment of Dr. Nurit Tweezer-Zaks as chief medical officer, effective as of August 18, 2025. * Tweezer-Zaks, who has served on PolyPid's board... Full story

Yahoo Finance • 3 months ago

PolyPid appoints Dr. Tweezer-Zaks as chief medical officer

PETACH TIKVA, Israel - PolyPid Ltd. (NASDAQ:PYPD), a clinical-stage biopharma company with a market capitalization of $32.92 million, announced Tuesday the appointment of Dr. Nurit Tweezer-Zaks as Chief Medical Officer, effective August 18... Full story

Yahoo Finance • 5 months ago

PolyPid stock price target lowered to $14 at JMP on warrant dilution

JMP Securities lowered its price target on PolyPid Ltd. (NASDAQ:PYPD) to $14 from $16 on Monday, while maintaining its Market Outperform rating on the stock. The micro-cap biotech company, currently valued at $37.4 million, has seen its... Full story

Yahoo Finance • 5 months ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

The Company Anticipates that with this Additional Funding, PolyPid’s Runway would be Extended beyond Anticipated U.S. Food and Drug Administration (FDA) Approval of D-PLEX ‚ ‚€ ‚€.The Company Recently Announced Successful Topline Results... Full story

Yahoo Finance • 5 months ago

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

D-PLEX100 successfully met the primary efficacy endpoint, with statistically significant results (p<0.005) in 798 patients with large abdominal surgery incisions.The trial successfully met all key secondary efficacy endpoints, including a... Full story

Yahoo Finance • 6 months ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call an... Full story

Yahoo Finance • 6 months ago

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

PETACH TIKVA, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, will participate in a webcast presentation and host one-... Full story

Yahoo Finance • 10 months ago

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

PETACH TIKVA, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will pre... Full story

Yahoo Finance • 10 months ago

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

PETACH TIKVA, Israel, Jan. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter... Full story

Yahoo Finance • 2 years ago

PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Completed Production and Release of Three... Full story

Yahoo Finance • 2 years ago

PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

PETACH TIKVA, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Nurit Tweezer-Zaks,... Full story